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Abstract
Background
Tuberculosis (TB) still is a major worldwide health problem, with 10.4 million new cases in
2016. Only 5–15% of people infected with M. tuberculosis develop TB disease while others
remain latently infected (LTBI) during their lifetime. Thus, the absence of tests able to distin-
guish between latent infection and active tuberculosis is one of the major limits of currently
available diagnostic tools.
Methods
A total of 215 patients were included in the study as active TB cases (n = 73), LTBI subjects
(n = 88) and healthy persons (n = 54). Peripheral blood mononuclear cells (PBMCs) were
isolated from each patient and the LIOSpot® TB anti-human IL-2 ELISpot assay was per-
formed to test their proliferative response to M. tuberculosis antigens ESAT-6, CFP-10 and
Ala-DH. Statistical analysis was performed to define the sensitivity and the specificity of the
LIOSpot® TB kit for each antigen used and to set the best cut off value that enables discrimi-
nation between subjects with active TB or latent TB infection.
Results
Comparing the LIOSpot® TB results for each tested antigen between uninfected and
infected subjects and between people with latent infection and active TB disease, the differ-
ences were significant for each antigen (p< 0.0001) but the ROC analysis demonstrated a
high accuracy for the Ala-DH test only, with a cut off value of 12.5 SFC per million PBMCs
and the Ala-DH ROC curve conferred a 96% sensitivity and 100% specificity to the test. For
the ESAT-6 antigen, with a best cut off value of 71.25 SFC per million PBMCs, a sensitivity
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of 86% and specificity of 36% was obtained. Finally, the best cut off value for CFP-10 was
231.25 SFC per million PBMCs, with a sensitivity of 80% and a specificity of 54%. Thus, as
for IGRA assays such as Quantiferon and T-Spot TB tests, ESAT-6 and CFP-10 are unable
to distinguish LTBI from active TB when IL-2 is measured. On the contrary, the IL-2 produc-
tion induced by Ala-DH, measured by LIOSpot® TB kit, shows high sensitivity and specificity
for active TB disease.
Conclusions
This study demonstrates that the LIOSpot® TB test is a highly useful diagnostic tool to dis-
criminate between latent TB infection and active tuberculosis in adults patients.
Introduction
Tuberculosis (TB) still is a major health problem worldwide. In 2016, there were 10.4 million
new estimated cases worldwide. TB ranks above HIV/AIDS as one of the leading causes of
death from an infectious disease; 1.7 million deaths were estimated in 2016 [1].
Incident TB cases reflect a little percentage of the global infection burden: indeed in the
great majority of immunocompetent persons, infection with Mycobacterium tuberculosis
(MTB) is initially contained by the host immune system, resulting in a latent TB infection
(LTBI) which is characterized by the presence of immune responses to MTB in the absence of
clinical, radiological and microbiological evidences [2]; 5–15% of the infected people develop
TB disease during their lifetime, being a reservoir of new active TB cases [1, 3, 4].
The tuberculin skin test (TST) and MTB specific interferon-gamma (IFN-γ) release assays
(IGRAs), such as QuantiFERON-TB Gold In-Tube (QFT-G-IT) assay (Cellestis/Qiagen, Car-
negie, Australia) and T-SPOT TB assay (Oxford Immunotec, Abingdon, UK) are still the main
tools used for the diagnosis of TB infection. Although the newer IGRAs show some improve-
ments over TST [5, 6, 7], neither diagnostic test can differentiate between LTBI, active TB or
past TB [8].
Since the reactivation of TB can be averted by preventive treatment, it is important to iden-
tify new biomarkers for the diagnosis of LTBI by setting a new in vitro diagnostic method for
differential diagnosis between active TB and LTBI.
Our group has studied this Ala-DH for more than 25 years and have published, for the first
time, its biochemical [9,10], molecular and 3-D structural characterization suggesting modi-
fied conformation in latent and active TB [11]. This enzyme has been implicated in adaptation
of M. tuberculosis to anaerobic dormant stage in LTBI. Ala-DH of M. tuberculosis is a unique
enzyme involved in peptidoglycan biosynthesis since it only accepts L-alanine as substrate in
contrast to Ala-DH from all other organisms studied, which also use serine as a substrate
[9,10]. This enzyme is missing in M. bovis and in M. bovis BCG making it highly specific to M.
tuberculosis as the cause of world-wide pulmonary and extra-pulmonary tuberculosis. Even
though this protein is present in other pathogenic mycobacteria such as M. marinum and M.
ulcerans, there is no overlap between symptoms of TB and the low prevalence diseases caused
by M. marinum or M. ulcerans. The same shall hold good for all other type of microorganisms
possessing Ala-DH enzyme. It is worth mentioning that ESAT6 and CFP10 have been used
world-wide in the Quantiferon and T-Spot kits and are regarded as specific to M. tuberculosis,
but these antigens are also present in M. marinum and M. ulcerans. To the best of our knowl-
edge, there are no reports of significant, false diagnosis by the use of the above mentioned
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IGRA tests showing that infection and diseases caused by non-tuberculous mycobacteria
(NTM) do not pose serious problems as far as cytokine based TB diagnosis is concerned. An
extensive, prospective cohort study of 210 BCG- vaccinated neonates in Southern India was
published by Dhanasekaran et al. [12] on effects of NTM infection on host biomarkers poten-
tially relevant to TB management. The results showed an up-regulation of IL-2 in children
with TB disease but not in NTM subjects confirming our previous report on Ala-DH based
IL2 Elispot assay for differential TB diagnosis in children [13].
Given that Ala-DH is not specific for M. tuberculosis bacilli [14, 15] we cannot exclude that
other recombinant proteins would be useful for the setup of other TB diagnostic assays [16].
Although other authors also use IL-2 to detect response in MTB infected subjects [17, 18,
19] we previously showed, for the first time, that out of a number of M. tuberculosis antigens
tested including Ala-DH, ESAT6, CFP10, PstS1, HSPX, antigen 85B, only Ala-DH induced
IL2 production measured by an ELISPOT assay could clearly distinguish children with LTBI
from those with active TB [13]. No other antigen showed this excellent property as far as differ-
ential TB diagnosis is concerned [13].
Aim of the study
This study is focused on improving TB diagnosis by developing a new blood test to discrimi-
nate between active and latent TB infection according to the best cost/effectiveness ratio. A
new ELISpot test, called LIOSpot1 TB, with high specificity and sensitivity was developed
based on our previous home-made ELISpot. [13] The new LIOSpot1 TB assay, for the first
time, provided evidence that MTB Ala-DH antigen was able to stimulate IL-2 production in
active TB but not in LTBI.
Materials and methods
Patients and definition of study groups
This study was performed on peripheral blood samples collected from patients with confirmed
active TB, from subjects diagnosed with LTBI and from healthy donors, who were consecu-
tively enrolled during the period between September 2014 and August 2016 by the Careggi
University Hospital, Florence, Italy. Subjects below 18, pregnant women, HIV/AIDS and all
those people with any known immunocompromising condition (such as diabetes, hematologi-
cal malignancies, end stage kidney disease and immunosuppressive therapy) were excluded
from the study. None of the healthy patients had recent exposure to active pulmonary TB
cases.
Following the approval by the “Area Vasta Centro, Regione Toscana, Ethical Committee”
(BIO 14.013), each patient, previously informed of the aim of the study, signed an informed
consent.
All subjects were tested with TST (Sanofi Pasteur MSD SNC, Lyon, France) according to
the Mantoux method [20] and with the IGRA test QFT-G-IT according to the manufacturer’s
instructions [21].
The subjects enrolled in the study were classified as active TB patients, LTBI patients or
healthy people in accordance with the current guidelines [2, 22, 23].
Active TB patients, in addition to TST positivity and a generally positive QFT-G-IT that
can be negative in a certain number of cases, were detected through clinical, microbiological
and radiological findings. The diagnosis’ confirmation required MTB identification through
fluorescence microscopy, polymerase chain reaction (PCR) or cultural assays upon biological
samples, such as sputum or bronchoalveolar lavage (BAL) for respiratory diseases, tissue biop-
sies, drainage liquid or needle aspirates for extrapulmonary localizations. In particular, all
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samples were tested with auramin-rhodamine fluorescence microscopic examination to detect
acid-alcohol resistant bacilli (BAAR); PCR-based methods like Artus MTB PCR Kit (Qiagen,
Venlo, Netherlands) and GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA) were used to
identify the Mycobacterium strain and to detect rifampicine resistance; then mycobacterial-
specific solid and liquid culture media were used for the isolation of the infectious agent.
LTBI was diagnosed by a positive test for MTB infection in persons without history of BCG
vaccination or by both TST and IGRA positivity in BCG vaccinated subjects, provided the
exclusion of active TB by medical history, clinical, radiologic, and microbiologic evaluations
[21, 24, 25].
A subject without BCG vaccination and discordant results between TST and QFT-G-IT
was attributed to his study group based on the TST result according to the Mantoux method
that is still the standard test for LTBI diagnosis; however IGRAs are recommended to confirm
LTBI diagnosis in TST positive BCG vaccinated individuals [2, 5, 26]. Patients with assessed
TST and/or QFT-G-IT positivity and chest X-ray positivity and/or in the presence of cough
(N = 97) were tested for MTB identification through fluorescence microscopy, PCR and cul-
tural assays on biological samples. The MTB identification tests were not performed in subjects
with negative TST and negative QFT-G-IT.
Consequently to the diagnosis, the 215 patients were classified as active TB cases (n = 73),
LTBI cases (n = 88) and healthy individuals (n = 54). Table 1 summarizes data from the 215
patients enrolled in the study.
Reagents
Lymphoprep was purchased from Fresenius Kabi Morge AS (Axis-Shield, Oslo, Norway),
RPMI 1640 medium from Biochrome (Leonorenstr, Berlin), L-glutamine from Euroclone
(Italy), beta-mercaptoethanol from Sigma-Aldrich (Darmstadt, Germany) Na-pyruvate and
Non-essential aminoacids from Thermofisher scientific (Waltham, MA, USA), penicillin/
streptomycin from PAN biotech (Aidenbach, Germany), fetal bovine serum (HyClone, GE
Helathcare Life Science, Utah, USA).
LIOSpot1 TB (LIONEX GmbH, Braunschweig, Germany) is an anti-human IL-2 Elispot
kit containing M. tuberculosis ESAT-6, CFP-10 and Ala-DH recombinant antigens, all pro-
duced at LIONEX to a purity of more than 98% and endotoxin free; Phytohaemagglutinin
mitogen (PHA) was used as a positive control.
PBMCs isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples of each
enrolled patient, within 8 hours after venipuncture to ensure cell activity, by Ficoll-Hypaque
density gradient centrifugation. Briefly, blood was layered on top of Lymphoprep, density gra-
dient of 1.077 g/mL, and centrifuged at 800 x g for 25 minutes at room temperature (15–25˚C)
without brake. PBMCs layer was harvested and washed two times in PBS, pH 7.4. Cells were
counted using the Burker chamber and then transferred into RPMI 1640 complete medium
(supplemented with L-glutamine 1%, beta-mercaptoethanol 1%, Na-pyruvate 1%, non-essen-
tial aminoacids 1%, penicillin 50.000U and streptomycin 50 mg), with 5% fetal bovine serum
to obtain a concentration of 2.5x106 PBMCs/ml.
Anti-human IL-2 ELISpot assay
The LIOSpot1 TB anti-human IL-2 ELISpot kit contains a 96-well plate coated with anti-
human IL-2. First we added the positive control (PHA) and the negative control (medium) as
single determinations and the three different antigens ESAT-6, CFP-10 and Ala-DH in double
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determination (5μg/ml); then PBMCs from each patient were seeded in order to have 2.5x105
cells per 0.1ml/well, working under sterile conditions. The plate was incubated in a humidified
incubator at 37˚C, 5% CO2 for 16–24 hours: during incubation time the antigen will activate
specific cells to release IL-2 that will be captured by the antibody at the bottom of the well.
After the incubation time wells content was discarded and the plate was washed five times
with a wash buffer (PBS—0.05% Tween-20) before adding the anti-human IL-2 biotinylated
detection antibody to each well. After one hour of incubation, wash steps were repeated and
the conjugated horseradish peroxidase (HRP)-streptavidin solution was then added. The plate
was incubated again for one hour at room temperature (RT) and, after being washed as already
described, TMB (3,30,5,50-Tetramethylbenzidine) substrate solution was dispensed into each
well and incubated for ten minutes at RT in the dark, until spots were visible. Following the
development of spots, the wells’ content was discarded and a stop solution was used. The plate
was dried and the number of SFC (spot forming cells) was counted by an automated ELISpot
reader using the AID EliSpot Software Version 3.2.3.
The SFC count in PHA positive control wells should be more then 50 or show saturation to
confirm cellular functionality and vitality. In the negative control it would be expected to have
few or no spots; the number of SFC in the negative control is subtracted from the SFC mean
Table 1. Characteristics of the 215 subjects divided according to the diagnosis in the three study groups.
Healthy
N (%)
LTBI
N (%)
Active TB
N (%)
54 (25) 88 (41) 73 (34)
Age
Median (IQR)
46 (32–63) 46 (35.5–65) 39 (31–61.5)
Immigrants 27 (50) 45 (51) 48 (66)
BCG vaccinated 21 (38.8) 38 (43.2) 32 (43.8)
TST (mm)
<5 54 (100) 0 (0) 0 (0)
5 and <10 0 (0) 5 (5.8) 0(0)
10 and <15 0 (0) 13 (14.7) 8 (11)
15 0 (0) 70 (79.5) 65 (89)
QFT-G-IT
Negative 50 (92.65) 5 (5.7) 4 (5.48)
Positive 3 (5.5) 80 (90.9) 68 (93.15)
Indeterminate 1 (1.85) 3 (3.4) 1 (1.37)
Fluorescence microscopy
Positive Not
performed
0 (0) 42 (57.5)
Negative Not
performed
24 (100) 31 (42.5)
PCR-based tests
Positive Not
performed
0 (0) 73(100)
Negative Not
performed
24 (100) 0 (0)
MTB isolation from culture
Positive Not
performed
0 (0) 73(100)
Negative Not
performed
24 (100) 0 (0)
https://doi.org/10.1371/journal.pone.0197825.t001
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value of the wells containing the ESAT-6, CFP-10 and Ala-DH antigens. Results were
expressed as number of SFC per million of PBMCs.
Statistical analysis
Descriptive statistics were used for the calculation of absolute frequencies and percentages for
qualitative data, as well as for mean, median (IQR), and standard deviation of quantitative
data.
All distributions of ELISpot test results for healthy patients, LTBI subjects or active TB
patients were compared using the Mann-Whitney inferential test or the Student t-test.
P <0.05 was considered statistically significant.
Test performance in terms of sensitivity (ability of the test to identify the true positive sub-
jects) and specificity (ability of the test to identify the true negative subjects) was evaluated for
each antigen by a ROC (Receiving Operating Characteristic) curve, the elective validation
method of a quantitative diagnostic test in a population. The proportion of patients correctly
diagnosed, that is the test accuracy, is proportional to the area under the curve (AUC), which
can assume values between 0.5 (50% accuracy) and 1 (100% accuracy). According to the classi-
fication proposed by Swets the test is not accurate for AUC = 0.5, the test is poorly accurate for
0.5<AUC 0.7, the test is moderately accurate for 0.7 <AUC 0.9, the test is highly accurate
for 0.9 <AUC< 1 and the test is perfect for AUC = 1 [27]. The ROC curve also allows to iden-
tify the best cut off value that maximizes the difference between true positive subjects and false
positives ones; it is the best threshold value for anti-human IL-2 ELISpot result relative to each
specific antigen (ESAT-6, CFP-10 and Ala-DH) in order to discriminate between patients with
active TB and subjects with LTBI. To maximize both sensitivity and specificity, the Youden’s
index (= Sensitivity–[1- Specificity]) can be applied.
Finally, the correlation between the ELISpot diagnostic test for each antigen and the diag-
nosis performed on each patient using the current methods was calculated by Cohen’s Kappa
coefficient according to which there would be slight concordance for the value of k = 0.2, poor
concordance for the value of K in the range 0.2–0.4, moderate concordance for k value in the
range 0.4–0.6, substantial concordance for k value in the range 0.6–0.8, good concordance for
k value in the range 0.8–1.
Statistical analysis were performed with SPSS for Windows software version 20.0.
Results
Two hundred and fifteen subjects were enrolled in this study: 73 patients with active TB, 88
with LTBI and 54 as uninfected controls. We performed LIOSpot1 TB according to kit man-
ual on PBMCs isolated from a blood sample of every participant by stimulation with MTB
antigens such as ESAT-6, CFP-10 and Ala-DH; the T cell specific response to each antigen was
evaluated in terms of IL-2 production. (Table 2).
Mann-Whitney inferential test or Student t-test were used to compare ELISpot results for
IL-2, as SFCs per million PBMCs, between healthy patients, LTBI subjects and active TB ones
referring to each tested antigen. Comparing the results of infected and non-infected there were
significant differences for all the antigens (p0.0001); similarly, comparing the results of
patients in LTBI and the group of active TB patients there were significant differences for all
three antigens too (p0.0001) (Table 2).
ROC curve analysis was performed for each antigen in order to establish the best cut off of
the ELISpot test for IL-2 in discriminating between LTBI and active TB.
Considering the response to Ala-DH antigen, a best cut off value of 12.5 SFC per million
PBMCs to have a 96% sensitivity and 100% specificity was established. The area under the
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ROC curve was 0.971 (IC 95%: 0.939–1), so the test was highly accurate in correctly diagnosing
subjects with active disease and those with latent infection.
For the ESAT-6 antigen, with a best cut off of 71.25 SFC per million PBMCs, a sensitivity of
86% and specificity of 36% was obtained. The area under the ROC curve was 0.713 (IC 95%:
0.632–0.794), the test is moderately accurate. Finally, the best cut off for CFP-10 was 231.25
SFC per million PBMCs, with AUC = 0.693 (IC 95%: 0.611–0.774); The test had a low accu-
racy, with sensitivity of 80% and specificity of 54% (Fig 1).
Once the best threshold value for the ELISpot IL-2 result was set for each specific antigen to
discriminate between subjects with active TB and subjects with LTBI, the correlation between
ELISpot and TST, that is still the standard test for MTB infection diagnosis, was assessed for
every antigen by computing The Cohen’s Kappa coefficient and interpreting the data as
described above.
The concordance between the ELISpot test for IL-2 and the TST test for all the results
obtained in the 215 patients with Ala-DH, ESAT-6 and CFP-10 is: 92.56% (k = 0.82 very good
concordance), 77.2% (k = 0.53, moderate concordance) and 63.7% (k = 0.35, poor concor-
dance) respectively (Table 3).
The concordances between the different assays are shown in Table 4. The five patients with
indetermined Quantiferon were excluded by this statistical analysis. ELISpot test for IL-2 and
the QFT-G-IT test for all the results obtained in the 210 patients with Ala-DH is 57.1%
(k = 0.25 poor concordance), with ESAT-6 is 79.5% (k = 0.57 moderate concordance) and with
CFP-10 is 71% (k = 0.44, moderate concordance). These results are in agreement with results
presented in this report since not all QFT-G-IT positive subjects were TB patients.
Discussion
Up to now, there are no biomarkers allowing to differentiate between active TB and LTBI.
During LTBI, MTB lives in a non-replicating state, enclosed into the granuloma structure, as
long as the host remains immunocompetent; in this period the bacillus still maintains the abil-
ity to reactivate and produce active disease when the host immune response is impaired [28,
29].
Studying gene expression profiles and proteomic analysis in both active and quiescent
mycobacteria, a number of genes that are differently regulated during the latency phase have
been found, in comparison to those expressed during active infection [11, 30]. Different anti-
gens of latency are currently known, several of them were identified in the DosR-regulon [31,
32, 33]. Another gene, Rv2780, that encode L-alanine dehydrogenase (Ala-DH), was found to
be over-expressed during the MTB dormancy phase, under nutrient starvation and lack of oxy-
gen regimes [15, 30, 34].
Table 2. IL-2 based ELISpot test results for the 215 enrolled patient.
Healthy (n = 54) LTBI (n = 88) Active TB (n = 73) P
(Healthy vs infected)
P
(Latent vs active disease)
Ala-DH 0
(0;0)
7.5
(2.5;10)
280
(85;1120)
p0.0001 p0.0001
ESAT-6 2.5 (0;17.5) 180
(30;340)
392,5
(140;1300)
p0.0001 p0.0001
CFP-10 0
(0;15)
192.5 (77.5;660) 480
(325;1590)
p0.0001 p0.0001
IL-2 based ELISpot test results for the 215 enrolled patients, clustered according to the diagnosis. The values are expressed as mean and interquartile range of SFC per
million PBMCs.
https://doi.org/10.1371/journal.pone.0197825.t002
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MTB Ala-DH catalyzes reversible conversion of pyruvate to alanine, and glyoxylate to gly-
cine concurrent with the oxidation of NADH to NAD [14] to maintain the optimal NADH/
NAD ratio during anaerobiosis in preparation of eventual regrowth, and during the initial
response during reoxygenation [15].
Thus MTB Ala-DH was thought to be a useful tool to discriminate between LTBI and active
TB [35] and our previous study demonstrates that this antigen is able to stimulate IL-2 produc-
tion in active TB but not in LTBI in a children population [13]. Given these findings, in the
Fig 1. Receiver operator characteristic (ROC) curve. A ROC curve (blu line) plot of the LIOSpot1 TB is shown,
illustrating sensitivity and specificity for Ala-DH (A), ESAT-6 (B) and CFP-10 (C) to discriminate subjects with active
TB from LTBI ones. AUC is the area delimited by the ROC curve and the green reference line.
https://doi.org/10.1371/journal.pone.0197825.g001
Table 3. Concordance between TST and IL-2 based ELISpot for each antigen in the study, for all the enrolled
subjects.
TST vs ELISpot Ag Concordance(%)
Cohen’s Kappa (k)
TST vs ELISpot ALA-DH 92.56%, k = 0.82
TST vs ELISpot ESAT-6 77.2%, k = 0.53
TST vs ELISpot CFP-10 63.7%, k = 0.35
https://doi.org/10.1371/journal.pone.0197825.t003
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present paper we aimed to confirm our result in an adults cohort tested with the LIOSpot1
TB kit, an ELISpot assay developed to detect IL-2 production by T cells stimulated with three
MTB antigens, like ESAT-6, CFP-10 (also used in IGRAs) and Ala-DH.
Cytokines play an important role in cell mediated immune responses to MTB infection.
The IFN-γ production by activated T cells has been widely considered to play a crucial role in
protection against MTB infection [28].
In the last decade, IGRAs became a landmark in the diagnosis of MTB infection. However,
these assays do not discriminate between latent infection and active tuberculosis disease, as
TST.
The choice of setting the LIOSpot1 TB assay on IL-2 cytokine production is due to the fact
that recent studies demonstrate the importance of this cytokine to discriminate between latent
and active tuberculosis infection, thus being a new possible diagnostic biomarker [35, 36, 37,
38]; based on the fact that IL-2 is significantly differentially produced by individuals with LTBI
and active TB patients [37, 39, 40].
According to these findings, LIOSpot1 TB was set as an anti human IL-2 ELISpot assay
able to detect IL-2 production after PBMCs stimulation with ESAT-6, CFP-10 and Ala-DH of
MTB.
In our study, all the healthy subjects showed no significant production of IL-2 (SFC per mil-
lion of PBMCs) in response to T cell stimulation by the three different antigens: Ala-DH (0:
0–0), ESAT-6 (2.5: 0–17.5) and CFP-10 (0: 0–15). Furthermore it is of note that none of the 21
BCG-vaccinated healthy subjects gave positive IL-2 responses to Ala-DH. The LIOSpot1 TB
detected a significant production of IL-2 after stimulation with ESAT-6 (392.5: 140–1300),
CFP-10 (480: 325–1590) and with Ala-DH (280: 85–1120) in 73 patients group with active TB.
Among people in the LTBI group, despite the smaller but substantial production of IL-2 in
response to ESAT-6 and CFP-10 stimulation (180: 30–340 and 192.5: 77.5–660 SFC per million
of PBMCs respectively) compared to active TB cases, Ala-DH induced a very low amount of
IL-2 production by stimulated T cells (7.5: 2.5–10 SFC per million of PBMCs).
Even though comparing the LIOSpot1 TB results for each tested antigen between unin-
fected and infected subjects and between people with LTBI and active TB, all the differences
were significant (p< 0.0001), the ROC analysis demonstrated a high accuracy of the test only
for Ala-DH: with a cut off value of 12.5 SFC per million PBMCs, the Ala-DH ROC curve con-
ferred 96% sensitivity and 100% specificity to the test. Thus, the LIOSpot1 TB test is highly
accurate and is able to make a differential diagnosis between subjects with active TB and those
with LTBI.
For the ESAT-6 antigen, with a best cut off value of 71.25 SFC per million PBMCs, a sensi-
tivity of 86% and specificity of 36% was obtained. Finally, the best cut off value for CFP-10 was
231.25 SFC per million PBMCs, with sensitivity of 80% and specificity of 54%.
Despite the low specificity, these thresholds confer to the LIOSpot1 TB the ability to detect
true tuberculosis infection.
Table 4. Concordance between QFT-G-IT and IL-2 based ELISpot for each antigen in the study, for all the 210
enrolled subjects.
QFT-G-IT vs ELISpot Ag Concordance(%)
Cohen’s Kappa (k)
QFT-G-IT vs ELISpot ALA-DH 57.1%, k = 0.25
QFT-G-IT vs ELISpot ESAT-6 79.5%, k = 0.57
QFT-G-IT vs ELISpot CFP-10 71.0%, k = 0.44
https://doi.org/10.1371/journal.pone.0197825.t004
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Overall, the present study demonstrates that the LIOSpot1 TB test is a very useful diagnos-
tic tool to discriminate between LTBI and active tuberculosis infection.
Supporting information
S1 File. ELISpot supporting information. IL-2 based ELISpot results for each of the active
TB, LTBI patients and healthy subjects.
(PDF)
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